Bellicum Pharmaceuticals Inc  

(Public, NASDAQ:BLCM)   Watch this stock  
Find more results for Kevin D Huber´┐Ż
17.34
+0.01 (0.06%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.00 - 17.58
52 week 15.05 - 33.63
Open 17.23
Vol / Avg. 286,691.00/313,952.00
Mkt cap 459.40M
P/E     -
Div/yield     -
EPS -25.79
Shares 26.49M
Beta     -
Inst. own 60%
Sep 9, 2015
Bellicum Pharmaceuticals Inc at FBR Healthcare Conference Add to calendar
Aug 13, 2015
Q2 2015 Bellicum Pharmaceuticals Inc Earnings Call - Webcast
Aug 13, 2015
Q2 2015 Bellicum Pharmaceuticals Inc Earnings Release
Aug 11, 2015
Bellicum Pharmaceuticals Inc at Wedbush PacGrow Healthcare Conference
Jun 17, 2015
Bellicum Pharmaceuticals Inc Annual Shareholders Meeting
Jun 2, 2015
Bellicum Pharmaceuticals Inc at Jefferies Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -12540.48% -4715.75%
Operating margin -12744.05% -3248.36%
EBITD margin - -782.12%
Return on average assets -22.93% -79.69%
Return on average equity -23.32% -104.47%
Employees 35 -
CDP Score - -

Address

2130 W Holcombe Blvd Ste 800
HOUSTON, TX 77030-3307
United States - Map
+1-832-3841100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy, and dendritic cell vaccines. The Company's product candidates include BPX-501, BPX-201, BPX-401, BPX-601 and BPX-701. It is also engaged in other development programs, such as CIDeCAR for the treatment of solid tumors and CaspaCIDe TCR for the treatment of hematological cancers.

Officers and directors

James Farrell Brown Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Thomas J. Farrell President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Alan A. Musso CPA Chief Financial Officer, Treasurer
Age: 53
Bio & Compensation  - Reuters
Annemarie Moseley M.D., Ph.D. Chief Operating Officer, Senior Vice President - Clinical Development and Regulatory Affairs
Age: 59
Bio & Compensation  - Reuters
Ken Moseley J.D. Senior Vice President, General Counsel
Age: 58
Bio & Compensation  - Reuters
Peter L. Hoang Senior Vice President - Business Development and Strategy
Age: 43
Bio & Compensation  - Reuters
Kevin M. Slawin M.D. Chief Medical Officer, Chief Technology Officer, Director
Age: 54
Bio & Compensation  - Reuters
David M. Spencer Ph.D. Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Joseph Senesac Vice President - Manufacturing
Age: 44
Bio & Compensation  - Reuters
Reid M. Huber Ph.D. Director
Age: 42
Bio & Compensation  - Reuters